A joint venture between Fujifilm Kyowa Kirin Biologics and AstraZeneca has received a positive biosimilar opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Centus Biotherapeutics has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for its bevacizumab biosimilar (Equidacent) for multiple forms of cancer.
The reference product is Genentech’s Avastin. Centus, which is a joint venture between Fujifilm Kyowa Kirin Biologics and AstraZeneca, seeks indications for metastatic carcinoma of the colon or rectum; metastatic breast cancer; unresectable advanced, metastatic, or recurrent non—small cell lung cancer (NSCLC); advanced and/or metastatic renal cell cancer; epithelial ovarian, fallopian tube, or primary peritoneal cancer; and persistent, recurrent, or metastatic carcinoma of the cervix.
The CHMP opinion comes after Centus submitted clinical trial data as part of the marketing authorization application for the biosimilar, which included a comparative analysis of Equidacent and the reference product.
“I am delighted that CHMP decided to recommend the approval of the proposed biosimilar bevacizumab. We will continue our efforts to bring high quality and affordable biosimilars to patients throughout European countries,” said Atsushi Matsumoto, PhD, president and CEO of Fudifilm Kyowa Kirin Biologics, in a statement.
Clinical Trials of Equidacent
Phase 3 trial (AVANA) results demonstrated no clinically meaningful differences in terms of safety, efficacy, and immunogenicity between Equidacent and the reference product in patients with NSCLC.
Currently, another phase 3 trial is ongoing to compare the safety and efficacy of the biosimilar and reference product in combination with paclitaxel and carboplatin in patients with NSCLC.
A decision from the European Commission on whether the product can be marketed is expected in September 2020. If the product is approved, Centus would have marketing authorization in 27 European Union member states, the United Kingdom, and the European Economic Area member states of Norway, Iceland, and Lichtenstein.
As a joint venture between Fujifilm Kyowa Kirin Biologics and AstraZeneca PLC, Centus has exclusive license for the development, manufacture, and commercialization of Equidacent.
Recently, the FDA approved Fujifilm Kyowa Kirin Biologics's Hulio adalimumab biosimilar, although it won't appear on the US market until 2023. Hulio launched in Europe in 2018.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Bevacizumab Biosimilars Offer Promise for CRC Treatment, Wound Healing, and Cost Savings
February 28th 2024A review emphasizes that bevacizumab biosimilars demonstrate comparable efficacy to the reference product (Avastin) in the treatment of colorectal cancer (CRC) by tackling wound healing concerns in anorectal medicine.